First Light Asset Management LLC boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 416,579 shares of the biopharmaceutical company’s stock after purchasing an additional 1,968 shares during the quarter. Halozyme Therapeutics makes up 1.8% of First Light Asset Management LLC’s portfolio, making the stock its 21st biggest position. First Light Asset Management LLC owned approximately 0.31% of Halozyme Therapeutics worth $5,341,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Ameritas Investment Partners Inc. bought a new position in Halozyme Therapeutics in the first quarter worth $122,000. Teacher Retirement System of Texas bought a new position in Halozyme Therapeutics in the second quarter worth $129,000. Prudential Financial Inc. raised its holdings in Halozyme Therapeutics by 8.7% in the second quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 940 shares in the last quarter. Amalgamated Bank raised its holdings in Halozyme Therapeutics by 5.3% in the second quarter. Amalgamated Bank now owns 14,067 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 705 shares in the last quarter. Finally, Karp Capital Management Corp bought a new position in Halozyme Therapeutics in the first quarter worth $188,000. Institutional investors and hedge funds own 85.06% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/09/30/first-light-asset-management-llc-boosts-holdings-in-halozyme-therapeutics-inc-halo.html.

HALO has been the subject of a number of research reports. Piper Jaffray Companies set a $20.00 price objective on Halozyme Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 10th. Barclays PLC reiterated an “overweight” rating and issued a $16.00 price objective on shares of Halozyme Therapeutics in a report on Friday, June 23rd. Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Friday, August 25th. BidaskClub downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, July 1st. Finally, Jefferies Group LLC restated an “underperform” rating and set a $7.00 price target (up from $6.75) on shares of Halozyme Therapeutics in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $16.63.

Shares of Halozyme Therapeutics, Inc. (HALO) traded down 0.17% during trading on Friday, hitting $17.37. The stock had a trading volume of 908,426 shares. Halozyme Therapeutics, Inc. has a 12 month low of $8.18 and a 12 month high of $17.62. The company’s market cap is $2.33 billion. The stock has a 50-day moving average price of $13.01 and a 200 day moving average price of $13.28.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. The company had revenue of $33.80 million during the quarter, compared to the consensus estimate of $31.76 million. The company’s revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.21) earnings per share. Equities analysts expect that Halozyme Therapeutics, Inc. will post ($0.22) EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Stock Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related stocks with our FREE daily email newsletter.